Pancreatic Cancer Therapy Review: From Classic Therapeutic Agents to Modern Nanotechnologies.
Pancreatic cancer remains one of the most lethal cancers worldwide, with an extremely poor prognosis. This cancer is considered the 5th leading cause of cancer related death. The median survival after diagnosis is generally 2-8 months and five-year survival rate is less than 5%. In recent years, nanotechnology is emerging as a rising approach for drug delivery since it has opened up new landscapes in medicine through introduction of smart nanocarrier systems that can selectively deliver the therapeutic agent in a specific region and in appropriate levels, reducing the adverse side effects. This review covers the main delivery systems developed so far for anticancer drug delivery to the pancreas over a period of 20 years, from polymeric to lipidic-based nanosystems, with a particular emphasis on albumin as core material.
CBIOS, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, 1749-024 Lisboa. Poland.
Ana
A
Rebelo
Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá, Ctra. A2km 33,600 Campus Universitario, 28871 Alcalá de Henares. Spain.
Jesus
J
Molpeceres
iMed.ULisboa - Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa. Portugal.
Patrícia
P
Rijo
CBIOS - Research Center for Biosciences & Health Technologies, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande, 376, 1749-024 Lisboa. Portugal.
Catarina Pinto
CP
Reis
D000418:Albumins / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D016503:Drug Delivery Systems; D006801:Humans; D007167:Immunotherapy; D053758:Nanoparticles / Q000008:administration & dosage / Q000627:therapeutic use; D036103:Nanotechnology; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000628:therapy*; D015398:Signal Transduction
D000418:Albumins; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
Pancreatic cancer; drug delivery; nanoparticles; polymers; signaling pathways; targeted therapy